Mar 16, 2026 | Structure Therapeutics Oral GLP-1 Data Rivals Orforglipron; BioMarin Halts Voxzogo Studies

Structure's aleniglipron delivers 16.3% weight loss in Phase2 — challenging Lilly's orforglipron in the oral GLP-1 race. Plus BioMarin's Voxzogo safety halt, Aldeyra's reproxalap FDA decision, Rhythm's EMANATE miss ahead of Thursday PDUFA, and Bayer's Kerendia CKD expansion win.Visit us at https://thepharmacloseout.com/#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Structure Therapeutics, #aleniglipron, #GLP-1, #oral obesity, #BioMarin, #Voxzogo, #achondroplasia, #Aldeyra, #reproxalap, #dry eye, #Rhythm Pharmaceuticals, #Imcivree, #EMANATE, #Bayer, #Kerendia, #finerenone, #CKD, #CytomX, #varsetatug masetecan, #ADC, #colorectal cancer, #Eli Lilly, #Ebglyss, #atopic dermatitis, #GSK, #Amgen, #TrumpRx, #CDC vaccine schedule, #PDUFA, #Pfizer, #Lilly, #Merck, #J&J, #Sanofi